There is no shortfall of advocates heralding the benefits of medical cannabis, nor any lack of headlines on the tax benefit to states either. Just yesterday, Ohio was in the news with the House of Representatives passing a medical marijuana bill and sending it on to the Senate for their nod, and an expert panel in Florida estimated that the latest tweak to legal medical cannabis laws could tack on another $11.4 million in tax revenue.
In spite of rising acceptance, there isn’t any deficit of skeptics either, given that most scientific evidence is considered anecdotal. Vancouver-based Veritas Pharma (OTC: VRTHF)(CSE: VRT) wants to change that.
The young company, located at an industrial discovery park on The University of British Columbia campus, is working to develop medicinal cannabis cultivars – cannabis varieties cultivated through selective breeding – for diseases and conditions where data shows cannabis could be an effective treatment option. The company believes that chemically and pharmacologically profiling different cannabis cultivars can result in identifying disease-specific strains to serve as building blocks for new medicines.
Target indications for Veritas include epilepsy, chronic pain, post-traumatic stress disorder, muscle spasms and nausea.
In order to achieve these goals, Veritas needs cannabis to work with and the company said Tuesday that it has placed its first order for two popular cannabis strains, “Train Wreck” and “Northern Tonic,” with Whistler Medical Marijuana Corp. Whistler is set apart in Canada as one of only 19 cultivation and sales license holders for dried marijuana and one of only 15 licensed producers of fresh marijuana and cannabis oils in the country. It is also the first company in Canada to be certified as an organic medical marijuana producer by British Columbia’s Fraser Valley Organic Producers Association.
Verita selected Train Wreck and Northern Tonic first because of their well known cannabinoid traits.
Veritas chief executive Dr. Lui Franciosi said that this is only the beginning of orders between his company and Whistler, as scientists are eager to start the screening and assessment process. Additional orders of different strains are anticipated to be placed on a weekly basis going forward, according to Franciosi.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of PotNetwork.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://potnetwork.com/legal-disclaimer/.